Claims for Patent: 5,112,757

Summary for Patent: 5,112,757

Title:	Method for obtaining human hepatocyte cultures
Abstract:	A method for culturing human hepatocytes is disclosed. The method comprises associating a culture of human hepatocytes including a medium with cells of hepatic origin, these cells being different from the hepatocytes and being of the type insuring in vivo specific cellular interactions with the hepatocytes. The culture obtained maintains hepatocyte functions at a high level for an extended period of time.
Inventor(s):	Guguen-Guillouzo; Christiane (Rennes, FR), Guillouzo; Andre (Rennes, FR), Bourel; Michel (Rennes, FR)
Assignee:	Institut National de la Sante et de la Recherche (Paris, FR)
Application Number:	07/034,983
Patent Claims:	1. A method of culturing human hepatocytes comprising combining a first cell population comprising a culture of human hepatocytes including a medium, and a second cell population of mammalian epithelial cells of hepatic origin, said second cell population being from a different species with respect to said first cell population, cells of said second cell population being capable of forming numerous contacts with cells of said first cell population, whereby a co-culture is formed in which filamentous structures comprising collagen fibers appear in the intracellular spaces. 2. A method according to claim 1, wherein said epithelial hepatic cells are derived from established cell lines obtained from mammals. 3. A method according to claim 1 wherein said cells of hepatic origin are transformed cells. 4. A method according to claim 1 wherein said cells of hepatic origin are untransformed cells. 5. A method according to claim 1 wherein said human hepatocytes are obtained from livers of a human adult. 6. A method according to claim 1 wherein said human hepatocytes are obtained from livers of a human fetus. 7. A method according to claim 1 wherein said human hepatocytes are obtained from normal livers. 8. A method according to claim 1 wherein said human hepatocytes are obtained from pathological livers. 9. A method according to claim 1, further comprising after the combination step, the step of adding into the co-culture a hormone of the corticosteroid type. 10. A method according to claim 9 wherein said hormone is hydrocortisone hemisuccinate. 11. A method according to claim 9 wherein the adding step comprises the step of adding the hormone after aggregation of said hepatocytes and said cells of hepatic origin. 12. A method according to claim 10, wherein said adding step comprises adding a culture medium containing approximately 7.times.10.sup.-5 M to 7.times.10.sup.-7 M of hydrocortisone hemisuccinate. 13. A method according to claim 1 wherein said medium is serum-free. 14. A method according to claim 1 wherein said medium contains pig insulin, bovine albumin, and serum. 15. A method according to claim 14 wherein said serum is fetal calf serum. 16. A method according to claim 1, further comprising the step of selectively detaching said hepatocytes from said co-culture by incubation of said co-culture with a proteolytic enzyme capable of hydrolyzing collagen fibers in a medium without calcium, under conditions permitting slow action of said enzyme specific with respect to the hepatocyte populations, and then, subjecting the medium to stirring and centrifugation to remove the detached hepatocytes from the medium. 17. A method according to claim 16 wherein said proteolytic enzyme is collagenase. 18. A method according to claim 17 wherein the incubation of said co-culture is performed with collagenase at about 37.degree. C. for about 15 min., at a concentration of about 0.020 to 0.30% in buffered solution without calcium. 19. A method according to claim 1 wherein the combining step comprises adding said cells of hepatic origin to the hepatocyte culture upon aggregation of said hepatocyte culture. 20. A method according to claim 1 wherein said combining step comprises adding said cells of hepatic origin to said hepatocytes after said hepatocytes have been placed in culture. 21. A method according to claim 1, wherein said combining step comprises adding said cells of hepatic origin to pure hepatocyte populations after several days of culture, thus permitting the functions of said hepatocytes to be modulated. 22. An in vitro human hepatocyte co-culture capable of maintaining functioning hepatocytes for six weeks, comprising human hepatocytes and mammalian epithelial cells of hepatic origin but different from said hepatocytes and from a different species, said epithelial cells forming numerous contacts with the human hepatocyte cells. 23. A co-culture according to claim 22, further comprising numerous reticulin fibres formed about 24 hours after confluence of said cells of hepatic origin. 24. A co-culture according to claim 22 wherein said co-culture includes a heterogeneous extracellular material, formed essentially from fibronectin and collagen, around said hepatocytes and between said hepatocytes and said hepatic cells. 25. A method of culturing human hepatocytes comprising combining a first cell population comprising a culture of human hepatocytes including a medium, and a second cell population of hepatic origin, said second cell population being epithelial hepatic cells derived from cell lines obtained from rats, cells of said second cell population being capable of forming numerous contacts with cells of said first cell population, whereby a co-culture is formed in which filamentous structures comprising collagen fibers appear in the intracellular spaces. 26. An in vitro human hepatocyte co-culture capable of maintaining functioning hepatocytes for six weeks, comprising human hepatocytes and cells of hepatic origin which are rat epithelial cells said cells forming numerous contacts with said hepatocytes, and a heterogeneous extracellular material, formed essentially from fibronectin and collagen, around said hepatocytes and between said hepatocytes and said hepatic cells. 27. A co-culture according to claim 6, wherein said co-culture comprises hepatocytes from normal livers and wherein said collagen is formed of collagen III and collagen I.

Details for Patent 5,112,757

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2009-05-12